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Infantile functional gastrointestinal disorders are common in the first months of
life. Their pathogenesis remains unknown although evidences suggest multiple
independent causes, including gut microbiota modifications. Feeding type, influencing
the composition of intestinal microbiota, could play a significant role in the pathogenesis.
Previous studies supported probiotic supplementation success against colics, however
mainly Lactobacillus spp. were tested. The aim of this study was to evaluate the
effectiveness against functional gastrointestinal disorders of a Bifidobacterium breve
based probiotic formulation including in the study both breast-fed and bottle-fed
subjects. Two hundred and sixty-eight newborns were enrolled within 15 days from birth.
One hundred and fifty-five of them effectively entered the study and were randomized
in probiotic and placebo group, receiving the formulation for 90 days. The probiotic
formulation consists of a 1:1 mixture of 2 strains of B. breve prepared in an oily
suspension and administered in a daily dosage of 5 drops containing 108 CFU of each
strain. Absolute quantification of selected microbial groups in the faeces was performed
using qPCR. Anthropometric data, daily diary minutes of crying, number of regurgitations,
vomits and evacuations, and colour and consistency of stools were evaluated before and
after treatment. The study confirmed the positive role of breast milk in influencing the
counts of target microbial groups, in particular the bifidobacteria community. No adverse
events upon probiotic administration were reported, suggesting the safety of the product
in this regimen. B. breve counts increased significantly in all administered newborns
(p < 0.02). The study demonstrates that a 3 months treatment with B. breve strains
in healthy breast-fed newborns helps to prevent functional gastrointestinal disorders,
in particular reducing 56% of daily vomit frequency (p < 0.03), decreasing 46.5% of
daily evacuation over time (p < 0.03), and improving the stool consistency (type 6 at the
Bristol Stool chart instead of type 5) in those at term (p< 0.0001). Moreover, a significant
reduction (8.65 vs. 7.98 LogCFU/g of feces, p< 0.03) of B. fragilis in the bottle-fed group
receiving the probiotic formulation was observed.
Keywords: probiotic, Bifidobacterium breve, infant colic, functional gastrointestinal disorders, breastfeeding,
bottle-feeding, microbiota
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INTRODUCTION
Infant colic is a common disorder in the first 3 months
of childhood that affects up to 30% of newborns and is
characterized by paroxysmal, excessive, incontrollable crying
without identifiable causes (1). Wessel et al. (2) gave the first
definition of this disorder as a condition of crying or fussing that
lasts more than 3 h per day, more than 3 days per week. For
a clinical purpose, the Rome IV consensus group (3) recently
revised the diagnostic criteria including the age of newborn
(<5 months), giving less importance to the amount of crying
considering instead the prolonged and unsoothable character of
the crying episodes as well as irritability that cannot be prevented
or resolved by caregivers. Symptoms, such as flushing of the face,
meteorism, thighs flexion and flatulence, begin in the second
week of life, in both breast-fed and formula-fed infants, and
usually resolve spontaneously over time (4).
Infant colic represents a serious problem for the family,
because caregivers have difficulties in dealing with these
incontrollable crises often resulting in stress and concerns; a
prospective European multicenter study carried out by Vik
et al. (5) revealed that infantile colic and prolonged crying
are associated with high maternal depression scores. Similarly,
regurgitation, vomit and constipation frequently require a
pediatrician visit during the first 6 months of life and are often
responsible for feeding changes, and use of medical treatments
(6, 7). Moreover, several consequences were associated to the
presence of colics in the early stage of life: children with a history
of colics have a higher prevalence of functional gastrointestinal
disorders later in life (8) and children with migraine were more
likely to have experienced infantile colic than those without
migraine (7). Therefore, an effective preventive strategy against
functional gastrointestinal disorders is envisaged.
Despite 40 years of research, the etiology of colic crises and
other functional gastrointestinal disorders has not been fully
clarified. It has been suggested that a number of behavioral
factors (psychological and social), nutritional factors (food
hypersensitivity or allergy), intestinal dysmotility and low grade
intestinal inflammation can contribute to its occurrence (6, 9).
Being a typical disorder of the gastrointestinal tract, it is not
surprising that imbalance in the gut microbiota composition
has been suggested to play a role in the pathogenesis of these
conditions. The gut microbiota has a very close relation with
the host contributing to the normal human physiology: it can
provide a barrier for colonization of pathogens, synthesize
vitamins, and other beneficial compounds and stimulate the
immune system (10). The neonatal period is a crucial stage
for gastrointestinal colonization, a balanced composition of the
gut microbiota resulting in a positive effects on the host health
(11). Colicky infants have a reduced fecal-bacterial diversity and
stability, compared to the healthy ones. They also show a higher
prevalence of gram negative bacteria, especially coliforms, and a
reduced abundance of beneficial bacteria, such as lactobacilli and
bifidobacteria (12).
Diet has a dominant role in shaping the gut microbiota,
therefore the type of feeding in newborns has a certain impact
on the assessment of the intestinal microbial groups. Remarkable
differences were shown by Lee et al. (13): Actinobacteria
was the predominant phylum in breastfed newborns, followed
by Firmicutes and Proteobacteria; in contrast, in formula-
fed infants, the proportions of Actinobacteria and Firmicutes
were similar, followed by Proteobacteria. In addition, the
gut microbiota of formula-fed infants contains a significant
amount of the genera Escherichia, Veillonella, Enterococcus, and
Enterobacter, whereas the content of Lactobacillus was low.
The same work reports that the main genus in both breast-
and formula-fed infants is Bifidobacterium, but the proportion
resulted significantly higher in breastfed infants. The study of
Mazzola et al. (14) also showed a reduced Bifidobacterium spp.
count in mixed-fed infants (fed with at least 50% formula
milk) with respect to breastfed. On the contrary, a differential
representation of the genus Bifidobacterium was not detected in
breastfed infants compared to formula-fed, although differences
in the gut microbiota were observed in the two groups (15).
Moreover, these studies detected lower bacterial richness and
diversity in breastfed, probably for the presence of unique
oligosaccharides in breast milk, which serve as selectivemetabolic
substrates for a limited number of gut microbes (16).
Feeding type, influencing the composition of intestinal
microbiota, could play a significant role in the pathogenesis of
infant colics although after the first year of life these differences
are lost (17). A recent study focused on colicky and non-colicky
formula-fed infants, performed using FISH as bacterial counting
technique, revealed a lower concentration of total bacteria and a
higher abundance of Enterobacteriaceae in colicky formula-fed
infants (18).
Several studies support the use of probiotics as therapeutic or
preventive agents against various diseases, in particular enteric
disorders but also human pathology which are not apparently
linked to the microbial gut composition, such as allergies and
autoimmune diseases (19, 20). A treatment with probiotics,
whose beneficial effects on the gut microbiota disorders and
on human health are well known, may have a protective effect
from gastrointestinal disorders including colics and reduce the
symptoms associated, leading to a correct microbial colonization
in early infancy, when the gut microbiota is still in a period of
adjustment.
Many studies have focused on the administration of
Lactobacillus reuteri DSM 17938 as probiotic for the prevention
or reduction of symptoms of functional gastrointestinal
disorders, including colic, regurgitation, vomit and constipation
with successful results (6, 21, 22). In particular, Savino et al.
(23) evidenced a lower number of anaerobic gram negative
bacteria, enterobacteriaceae and enterococci in colicky newborns
that received L. reuteri compared to non treated babies.
However, other Lactobacillus species, such as L. delbrueckii
subsp. delbruekii DSM 20074 and L. plantarum MB 456, have
shown inhibitory activity against gas-forming coliforms and
they have the potential of being used in the management of
infant colic (24). Differently, the administration of bifidobacteria
for the treatment of these intestinal disorders remains scarcely
investigated, although their role in the healthy newborn gut
microbiota has been demonstrated as reviewed by Di Gioia
et al. (25). A previous in vitro study described the capability
of some strains belonging to Bifidobacterium genus, including
Bifidobacterium breve strains, of inhibiting in vitro the growth
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FIGURE 1 | Study flow diagram.
of pathogens typical of the infant gastrointestinal tract including
coliforms isolated from colicky newborns (26). Other studies
demonstrated the efficacy of B. breve, strains for the treatment
of different infant diseases: Li et al. (27) showed the usefulness
in promoting the colonization of B. breve and the formation
of a normal intestinal biota in low birth weight infants,
Wada et al. (28) described beneficial effects of this species in
immunocompromised pediatric patients on chemotherapy.
Moreover, recent studies have evidenced the effectiveness of
B. breve to reduce the risk of necrotizing enterocolitis in preterm
infants (29, 30). In addition, the two strains B. breve B632 and
BR03 have been investigated for their capability of colonizing
human intestine, stimulating the immune response, competing
against pathogens and their safety assessments have been also
demonstrated (26, 31, 32). A recent study also showed the
capability of these B. breve strains, used as probiotic for children
with celiac disease, to act as a “trigger” element for the increase of
other beneficial bacterial genus or phylum, like Firmicutes (33).
The aim of this study was to describe the effectiveness of
a B. breve based probiotic formulation administered both to
breast-fed and bottle-fed newborns in: 1) shifting the counts of
targeted fecal microbial groups; 2) preventing colic symptoms
and functional gastrointestinal disorders in a cohort of healthy
newborns.
MATERIALS AND METHODS
Study Design and Samples Collection
This was a double-blind, randomized, placebo-controlled clinical
trial (NCT03219931) approved by the Ethical Committee of the
Maggiore della Carità Hospital (CE 63/13). The newborns were
enrolled at the Department of Medical Sciences, Division of
Pediatrics, University of Piemonte Orientale “A. Avogadro” in
a period from November 2013 to September 2016. Newborns
were recruited at birth and enrolled within 15 days from birth
during the first visit (T0). Informed consent was obtained by
parents at the enrolment, in accordance with the local Ethics
Committee and Helsinki criteria. Patients were asked to perform
a second visit (T1) after 90 days of treatment. The number
of newborns assessed for eligibility [268], randomized [155],
and allocated to the placebo or probiotic group is shown
in Figure 1. They were recruited if healthy within 15 days
from birth and born adequate for gestational age. Exclusion
criteria were: 1) twin neonates; 2) treatments with any type
of drug within the enrolment; 3) treatments with probiotics;
4) smoking mothers; 5) family history for congenital diseases;
6) history of prolonged jaundice. No specific dietary restrictions
during lactation were recommended to the mothers, with the
exception of other products containing probiotics. Patients were
randomized using a computer-generated allocation sequence
in Placebo or Probiotic group (1:1). The study personnel and
parents were masked to the study group allocation. The original
idea of the study was to recruit an equal number of breast-fed
and bottle-fed newborns but, considering the difficulties in the
enrolment in bottle-fed ones, we decided to go on with a different
number of newborns belonging to the two groups (Figure 1).
The Probiotic group received a commercial probiotic
formulation Bifibaby R© (Probiotical S.p.A., Novara, Italy)
containing B. breve for 90 days (T1) and the Placebo group
received a placebo formulation for the same period. Probiotic
formulation was a 1:1 mixture of 2 strains, B. breve BR03 (DSM
16604) and B. breve B632 (DSM 24706) prepared in an oily
suspension, administered in a daily dosage of 5 drops containing
108 CFU of each strain. Placebo was prepared with the same
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TABLE 1 | Primer sequences and qPCR conditions used in the different assays.
Microorganism target Primer Sequence (5′-3′) Amplicon length (bp) References
Escherichia coli Eco-F GTTAATACCTTTGCTCATTGA 340 (34)
Eco-R ACCAGGGTATCTAATCCTGTT
C. difficile Cdiff-F TTGAGCGATTTACTTCGGTAAAGA 114 (35)
Cdiff-R TGTACTGGCTCACCTTTGATATTCA
Bifidobacterium spp. Bif-F TCGCGTCYGGTGTGAAAG 243 (36)
Bif-R CCACATCCAGCRTCCAC
Lactobacillus spp. Lac-F GCAGCAGTAGGGAATCTTCCA 349 (37)
Lac-R GCATTYCACCGCTACACATG
Bacteroides fragilis group Bfra-F CGGAGGATCCGAGCGTTA 92 (38)
Bfra-R CCGCAAACTTTCACAACTGACTTA
B. breve F _IS GTGGTGGCTTGAGAACTGGAT AG 118 (39)
R_IS CAAAACGATCGAAACAAACACTAAA
P_IS TGATTCCTCGTTCTTGCTGT
Enterobacteria Ent-F ATGGCTGTCGTCAGCTCGT 385 (40)
Ent-R CCTACTTCTTTTGCAACCCACTC
excipients without probiotic strains using an identical form of
package.
Clinical Monitoring
Delivery and birth data were collected during the first visit.
Anthropometric data (weight, height, head circumference) and
type of feeding information were collected at both the first (T0)
and second visit (T1).
Parents were asked to record on a daily diary minutes of
inconsolable crying according to a validated questionnaire (41).
They also recorded daily number of regurgitations, vomits, and
evacuations, and colour and consistency of stools. The Bristol
Stool Form Scale for children was given to parents (42). Colic was
diagnosed according to the Rome IV consensus group (3).
Parents were also asked to report any adverse event
(in particular constipation, vomit, allergic reactions, illness),
treatments, number and type of infections, or abdominal pain
occurred during the trial period. The adherence was monitored
by biweekly phone calls, counting empty vials, and checking daily
dairies.
Stool Samples Collection
Faecal samples of newborns were collected twice, on enrolment
(T0) and at the end of the intervention with probiotic/placebo
(T1). The analyzed groups were therefore: Probiotic T0,
Placebo T0, Probiotic T1, Placebo T1. Faecal samples were
frozen immediately after collection at −80◦C, in numbered
screw-capped plastic containers, until they were processed for
DNA extraction. Researchers performing DNA extraction and
molecular analyses (qPCR) were blind to the group identity of
patients (Probiotic or Placebo group).
DNA Extraction From Faecal Samples
DNA was extracted from 200mg of faeces (preserved at −80◦C
after collection) using the QIAamp DNA Stool Mini Kit
(Qiagen, West Sussex, UK) with a slight modification of the
standard protocol: a supplementary incubation at 95◦C for
10min of the stool sample with the lysis buffer was added
to enhance the bacterial cell rupture (43). Extracted DNA
was stored at −80◦C. The purity of DNA was determined
by measuring the ratio of the absorbance at 260 and 280 nm
(Infinite R©200 PRONanoQuant, Tecan,Mannedorf, Switzerland)
and the concentration was evaluated by Qubit R© 3.0 Fluorometer
(Invitrogen, Life Technologies, CA, USA).
Absolute Quantification of Selected
Microbial Groups Using Quantitative PCR
(qPCR)
Quantification of selected microbial groups or species
usually monitored in studies related to infants (38, 43), i.e.,
Bidobacterium spp., Lactobacillus spp., Bacteroides fragilis group
(comprising the most abundant species in human B. fragilis,
B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), B. breve,
Clostridium difficile, Escherichia coli, and total enterobacteria,
was performed with real-time PCR on DNA extracted from
stool samples. The assays were carried out with a 20 µL
PCR amplification mixture containing 10 µL of Fast SYBR R©
Green Master Mix (Applied Biosystems, Foster city, CA, USA)
optimized concentrations of primers (Tables 1, 2), molecular
grade H2O and 2 µL DNA obtained from faecal samples at a
concentration of 2.5 ng/µL. B. breve analysis was performed
using a TaqMan assay containing 12.5 µL of Universal TaqMan
master mix (Applied Biosystems, Foster city, CA, USA) 300 nM
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TABLE 2 | qPCR amplification protocols and primer concentrations.
Target bacteria Initial denaturation Denaturation Annealing N. cycles Fw (nM) Rev (nM)
E. coli
Eco-F/Eco-R 95◦C – 20 s 95◦C – 3 s 60◦C – 30 s 40 400 400
C. difficile
Cdiff-F/Cdiff-R 95◦C – 20 s 95◦C – 3 s 60◦C – 30 s 40 250 250
Bifidobacterium spp.
BifTOT-F/BifTOT-R 95◦C – 20 s 95◦C – 3 s 60◦C – 35 s 40 200 300
Lactobacillus spp.
Lac-F/Lac-R 95◦C – 20 s 95◦C – 3 s 63.5◦C – 30 s 40 200 200
of each primers and 100 nM of probe labeled with the 5′ reporter
dye 6-carboxyfluorescein and the 3′ quencher NFQ-MGB
(Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands).
The number of PCR cycles was 40.
The primer concentrations were optimized through primer
optimization matrices in a 48-well plate and estimating the
best Ct/1Rn ratio. The different primers were also checked for
their specificity utilizing the database similarity search program
nucleotide-nucleotide BLAST (44). Moreover, to evaluate the
specificity of amplification, analysis of product melting curve
was performed after the last cycle of each amplification. The
data obtained from the amplification were then converted to
obtain the number of bacterial cells (Log CFU/g faeces) in
accordance with the rRNA copy number available at the rRNA
copy number database (45). Standard curves were constructed
using 16S rRNA PCR products of type strains of each target
microorganism; the standard microorganisms used were B. breve
ReO2, Lactobacillus plantarum ATCC 14917, B. fragilis DSM
2151, B. breve B632 DSM 20213, Clostridium sporogenes ATCC
319, E. coli ATCC 8739. PCR products were purified with a
commercial DNA purification system (NucleoSpin R© Extract II
kit, MACHEREY-NAGEL GmbH & Co. KG, Germany) and the
concentrationmeasured spectrophotometrically at 260 nm. Serial
dilutions were performed and 102, 103, 104, 105, 106, 107 copies of
the gene per reaction were used for calibration. Sample reactions
were conducted in triplicate, with a negative control per each
reaction.
Statistical Analysis
Data were expressed as mean ± SD. Skewed variables were log
transformed. Daily data were divided in 9 categories representing
the mean of 10 consecutive days (from 0 to 90 day).
According to the primary outcome, a sample of 58 individuals
per group has been estimated to be sufficient to demonstrate a
difference between placebo and probiotics of 0.70 Log CFU/g of
bifidobacteria with a SD of 1.6, a 90% power, and a significance
level of 95%, and a drop-out rate of 20% according to published
data already available during the protocol design (32). According
to the secondary outcome, a sample of 55 individuals per
group has been evaluated sufficient to reduce of 30% the
proportion of gastrointestinal disorders (colic, regurgitation,
vomit, constipation) with an estimated prevalence of 40%,
according to literature (1, 6).
Data of microbial counts were subjected to Shapiro test
and Bartlett test in order to verify the normal distribution of
data and homogeneity of variances. The baseline characteristics
were compared with a Fisher’s exact test for categorical
variables and a two sample t-test or the Welch’s t-test when
appropriate for continuous variables. A two-way repeated
measure ANOVA was performed to evaluate the time effect,
the treatment effect and the interaction effects (model 1) on
the dependent variables (minutes of crying, stool characteristics,
episodes of vomits and regurgitation, microbial counts). Sum of
squares type III was used. The following covariates were also
subsequently introduced: sex, type of delivery (vaginal, caesarean,
operative), intrapartum antibiotic prophylaxis (IAP), gestational
age, neonatal weight (model 2). Model 3 also included the
type of feeding during the 90 days (breast-, bottle-, mixed-
feeding). Furthermore, in model 2 and 3, weight, length, and
head circumference were also corrected for the corresponding
variable at birth. All the statistical analyses were performed using
R Statistical Software and SPSS for Windows version 17.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Baseline Characteristics of Enrolled
Newborns
At birth, 268 newborns were assessed for eligibility and their
parents accepted the study. One hundred and ten did not
enter the study because failed to present to the enrollment visit
(46), refused the study that day (47) or were excluded due
to antibiotic treatments after birth (5). The 158 subjects were
assigned randomly to placebo or probiotic group. Three of them
were lost at the follow-up and were excluded (Figure 1). Of the
155 newborns who entered in the protocol, 130 were breast-fed
(59 placebo, 71 probiotics) and 25 were bottle-fed (14 placebo, 11
probiotics). Eighty-one were males, and 74 females. Moreover,
139 neonates were born by vaginal, 10 by cesarean, and 6 from
operative delivery. All the enrolled mothers were healthy without
suffering of chronic diseases. Fifteenmothers received IAP. Three
mothers have an episode of flu during the study (2 subjects in the
breastfeeding group and 1 subject in the formula feeding group).
No mother was treated with antibiotics during lactation.
Table 3 represents clinical data and microbiological fecal
counts at baseline in the two groups of allocation (placebo and
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TABLE 3 | Auxological characteristics of the whole cohort at baseline (T0)
according to the allocation treatment.
Placebo Probiotic
Gender (M/F) 34/39 47/35
Gestational age (weeks) 39.1 ± 1.2 39.3 ± 1.0
Neonatal weight (g) 3307.9 ± 397.5 3298.5 ± 362.7
Length (cm) 50.1 ± 2.0 50.1 ± 1.7
Head circumference (cm) 34.2 ± 1.4 33.9 ± 1.1
Delivery (V/C/O) 63/7/3 76/3/3
Days of life 10.6 ± 1.9 10.4 ± 2.4
Breast-/Bottle-feeding 59/14 71/11
Daily crying (min) 25.5 ± 28.8 28.8 ± 37.7
Stool frequency 3.8 ± 1.8 4.1 ± 1.9
Regurgitation episodes 1.7 ± 1.8 1.6 ± 1.4
Vomit episodes 0.1 ± 0.2 0.2 ± 0.4
Data are expressed as mean ± SD. C, cesarean; O, operative; V, vaginal.
TABLE 4 | Mean counts (Log CFU/g of faeces) of different microbial groups
analyzed in stool samples of the whole cohort.
Target Probiotic T0 Probiotic T1 Placebo T0 Placebo T1
Bifidobacterium spp. 7.00 ± 1.41 7.51 ± 0.88 6.88 ± 1.14 7.29 ± 1.06
B. breve 4.45 ± 1.85 6.40 ± 1.31* 4.54 ± 1.5 5.33 ± 1.5
Enterobacteria 6.54 ± 1.23 6.38 ± 1.14 6.02 ± 1.4 6.5 ± 1.02
E. coli 6.72 ± 1.93 7.2 ± 1.36 6.35 ± 2.07 7.42 ± 1.24
Lactobacillus spp. 6.56 ± 1.28 5.60 ± 1.23 6.22 ± 1.06 5.28 ± 1.48
B. fragilis group 7.44 ± 2.14 7.62 ± 1.97 6.79 ± 2.19 7.23 ± 2.00
C. difficile 2.66 ± 1.48 2.82 ± 1.50 2.60 ± 1.32 3.06 ± 1.58
*Significant changes at t-test (p < 0.02).
probiotic neonates). Only Lactobacillus spp. counts were higher
in the placebo group than in the probiotic group at baseline.
Because it is well-known that feeding modulates gut microbial
composition as well as clinical presentation also in neonates,
we investigated if breast- and bottle-fed babies were different
at baseline. Supplementary Table 1 represents clinical data and
microbiological fecal counts at baseline in the two groups (breast
fed and bottle-fed neonates). Crying time (p < 0.05) and stool
frequency were higher (p< 0.04) and regurgitation episodes were
less frequent (p< 0.05) in breastfed infants. Total enterobacteria
(p < 0.004), E. coli (p < 0.03), and B. fragilis group (p < 0.01)
counts were lower in breastfed than in bottle-fed newborns, also
when corrected for confounders (sex, gestational age, neonatal
weight, type of delivery, IAP, and days of life at the entry
date).
Microbiological Results in Whole Cohort
After Probiotic and Placebo Administration
Table 4 shows the average crude microbial count obtained
from the two groups of samples: probiotic and placebo. This
analysis showed a significant increase of B. breve counts after 3
months. The other microbial groups did not show any significant
difference.
Following this first evaluation and considering the different
sample dimension of breast- and bottle-fed newborns as well
as differences of baseline microbial counts in these two groups,
an analysis separating breastfed from bottle-fed newborns was
carried out.
Data Evaluation of Probiotic Treatment on
Breastfed Newborns
At baseline, the placebo group had less stool frequency
(p< 0.03) and lower enterobacteria counts than the probiotic one
(p < 0.01), also when corrected for confounders (sex, gestational
age, neonatal weight, type of delivery, and days of life at the entry
date). Themarginal means for stool frequency and enterobacteria
counts are: 3.2 ± 0.4 vs. 4.3 ± 0.3 (p < 0.01), and 5.86 ± 0.36 vs.
6.01± 0.38 Log CFU/g, (p< 0.03), respectively.
The compliance to the treatment was high. All the parents
answered to the phone calls. 98.7% of them brought back
correctly the empty vials. No adverse events were reported. Three
infants (1 in placebo and 2 in probiotic) received simethicone for
several days (<30 days) due to regurgitations.
After 90 days, 100 (43 in placebo, 57 in probiotics) of the 130
neonates were still breastfed. In the remaining 30 infants, 7 were
bottle-fed (5 in placebo, 2 in probiotic), and the other 23 were in
mixed feeding (11 in placebo, 12 in probiotic).
Clinical Data
Considering clinical data, minutes of crying (p < 0.005)
decreased over time without an effect of treatment also in the
corrected models.
The number of the evacuation decreased over time
(p < 0.0001), with an effect of treatment in those born
after 40 weeks of gestational age (p < 0.03). Stool consistency
was more type 5 at the Bristol Stool Chart (p < 0.03) over
time. Children born after 40 weeks of gestational age had more
frequently type 6 at the Bristol Stool Chart in those in probiotics
(p< 0.0001).
Episodes of regurgitation decreased constantly over time
(p < 0.01) in the probiotic group diversely by placebo group
accordingly to different type of feeding (p< 0.03, Figure 2).
Episodes of vomits decreased significantly with time in the
probiotic group but not in the placebo group (p < 0.03).
Moreover, during the 90 days the prevalence of colic infants was
similar in the placebo (4 subjects, 6.8%) and probiotic group (6
subjects, 8.5%).
Interestingly, also auxological variables were modified. Infants
in probiotics had a lower increase in weight during the study in
those born with a cesarean delivery (p < 0.03; Figure 3), and in
those still breastfed or switched to bottle-fed during the study
(p< 0.005). Diversely, infants in probiotics had a higher increase
in head circumference in those bottle-fed or with amixed-feeding
(p< 0.01).
Table 5 describes marginal means of model 1. Supplementary
Table 2 describes also corrected models.
Microbial Data
Total Enterobacteria (p < 0.005), Bifidobacterium spp.
(p < 0.001) and E. coli (p < 0.001) changed within time,
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FIGURE 2 | Number of daily regurgitations. Probiotic group (continuous line)
and placebo group (dotted line). Breast-fed newborns (A); Bottle-fed
newborns (B); Mixed-fed newborns (C). Data are expressed as marginal mean
± SEM. Data are significant in interaction (p < 0.04; model 3). The residuals
are not homogenous across the groups.
but the significance was lost when corrected for confounders. C.
difficile did not change.
In those treated with probiotics, B. fragilis group members
decreased within time in those born vaginally, whereas increased
in the other infants (p < 0.04). Moreover, B. breve increased
within time in those treated with the probiotics (p < 0.04).
Microbiological data are reported in Table 6.
Data Evaluation of Probiotic Treatment on
Bottle-Fed Newborns
At baseline, placebo group had less Lactobacillus spp. counts than
probiotic one (p< 0.008). When corrected for confounders (sex,
gestational age, neonatal weight, and days of life at the entry
date), the statistical significance was lost, whereas B. fragilis group
counts were higher in the probiotic group (marginal means are
6.62± 0.53 vs. 8.62± 0.67 Log CFU/g, p< 0.02).
FIGURE 3 | Weight variation in 90 days. Probiotic group (gray bar) and
placebo group (black bar). Newborns born by vaginal delivery (A); Newborns
born by cesarean delivery (B); Newborns born by operative delivery (C). Data
are expressed as marginal mean ± SEM. Data are significant in interaction
(p < 0.03; model 2). T0: baseline. T1: after 90 days of placebo/probiotic.
Clinical Data
Considering clinical data in both crude and corrected analysis, no
changes were detected in minutes of crying, stool frequency and
consistency, episodes of vomits or regurgitations. No infants had
colic in both groups. Weight (p< 0.0006), length (p< 0.01), and
head circumference (p < 0.005) increased with time without an
effect of the treatment.
Microbial Data
Total enterobacteria and E. coli did not change over time.
Bifidobacterium spp. (p < 0.02) and C. difficile increased
(p< 0.04) with time without a treatment’s effect. In those treated
with probiotics, B. fragilis group (p< 0.03) decreased and B. breve
increased (p< 0.03), respectively with time. Microbiological data
are reported in Table 7.
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TABLE 5 | Clinical and anthropometric variations in the breast-fed group obtained
with multivariable analysis of repeated measure.
Target Probiotic T0 Probiotic T1 Placebo T0 Placebo T1
Crying(min) 25.4 ± 4.5 19.3 ± 2.9 32.1 ± 5.6 20.5 ± 3.7
Stool frequency 4.3 ± 0.2 2.1 ± 0.1 3.9 ± 0.2 2.0 ± 0.1
Stool color 6.0 ± 0.1 5.7 ± 0.1 6.0 ± 0.1 6.0 ± 0.1
Stool consistency 5.8 ± 0.1 5.7 ± 0.1 6.0 ± 0.1 5.6 ± 0.1
Regurgitations 2.0 ± 0.2 1.6 ± 0.2 1.8 ± 0.2 2.0 ± 0.3
Vomits 0.25 ± 0.05 0.11 ± 0.06* 0.10 ± 0.05 0.20 ± 0.07
Weight (g) 3310.9 ± 43.7 3465.6 ± 57.4 3321.5 ± 48.0 3452.2 ± 62.9
Length (cm) 50.1 ± 0.2 51.5 ± 0.2 50.2 ± 0.2 51.5 ± 0.2
HC (cm) 33.9 ± 0.1 34.9 ± 0.1 34.3 ± 0.1 35.0 ± 0.1
All values are expressed as marginal means ± standard error. HC, head circumference.
*Significance in interaction (time * treatment) effect (p < 0.03).
TABLE 6 | Mean counts (Log CFU/g of faeces) of different microbial groups
analyzed in stool samples of breast-fed newborns.
Target Probiotic T0 Probiotic T1 Placebo T0 Placebo T1
Bifidobacterium spp. 7.11 ± 0.38 7.91 ± 0.27 6.59 ± 0.34 7.78 ± 0.24
B. breve 4.64 ± 0.50 6.10 ± 0.47* 4.40 ± 0.48 5.86 ± 0.46
Enterobacteria 6.01 ± 0.38 6.55 ± 0.35 5.86 ± 0.36 6.46 ± 0.34
E. coli 6.70 ± 0.57 7.46 ± 0.51 6.40 ± 0.54 7.06 ± 0.48
Lactobacillus spp. 6.22 ± 0.33 5.55 ± 0.33 6.28 ± 0.29 6.27 ± 0.35
B. fragilis group 6.34 ± 0.64 7.33 ± 0.61 6.31 ± 0.61 6.45 ± 0.58
C. difficile 2.70 ± 0.42 2.89 ± 0.48 2.82 ± 0.37 3.01 ± 0.42
All values are expressed as marginal means ± standard error. *Significance in interaction
(time * treatment) effect (p < 0.04).
TABLE 7 | Mean counts (Log CFU/g of faces) of different microbial groups
analyzed in stool samples of bottle-fed newborns.
Target Probiotic T0 Probiotic T1 Placebo T0 Placebo T1
Bifidobacterium spp. 6.80 ± 0.36 7.56 ± 0.36 6.79 ± 0.30 7.35 ± 0.30
B. breve 4.20 ± 0.35 6.42 ± 0.37* 4.11 ± 0.31 5.09 ± 0.33
Enterobacteria 7.30 ± 0.41 6.97 ± 0.34 6.75 ± 0.36 7.14 ± 0.30
E. coli 7.91 ± 0.95 7.38 ± 0.62 6.67 ± 0.66 7.51 ± 0.54
Lactobacillus spp. 6.81 ± 0.29 6.00 ± 0.35 6.05 ± 0.26 6.39 ± 0.31
B. fragilis group 8.65 ± 0.61 7.98 ± 1.84* 7.56 ± 0.56 8.33 ± 0.51
C. difficile 2.54 ± 0.44 3.16 ± 0.52 2.59 ± 0.39 3.35 ± 0.46
All values are expressed as marginal means ± standard error. *Significance in interaction
(time * treatment) effect (p < 0.03).
DISCUSSION
The use of bifidobacteria as probiotics in infants is established
for some enteric diseases, the most common of which is diarrhea
(25). However, although in vitro studies support the use of
bifidobacteria against gas-forming coliforms (26), no clinical
trials have been performed up to now on their use against infant
colics. This work was focused on the evaluation of the effects
on functional gastrointestinal symptoms, including colics, of
integration of the infant diet with a B. breve based probiotic
formulation.
The study has clearly shown the capability of the administered
B. breve strains to survive to the gastric transit and to reach
the neonatal intestine. In fact, although B. breve was detected in
all fecal samples, a significant increase was shown upon strain
administration. In agreement with Lee et al. (13), a reduction
of Lactobacillus counts was observed in all groups of newborns
over time and this is particularly evident in the probiotic treated
group. This could be related to a high ability of Bifidobacterium
spp. to influence gut microbiota composition, by enhancing the
blooming of some species and reducing others, as observed in
other studies regarding Bifidobacterium administration (25).
Feeding type is known to have a crucial role in shaping
the infant intestinal microbiota (25, 48). Our study shows that,
at the enrolment, when 7–15 days of breast- or bottle-feeding
had already been done, some differences were present in the
groups with different feeding type: total enterobacteria and E. coli
counts were higher in bottle-fed than in breast-fed newborns,
also when corrected for confounders. In addition, higher counts
of B. fragilis were found in bottle-fed infants at the baseline, in
agreement with the higher risk of infection generally observed in
non breast-fed infants (49). This higher count was also evident
after treatment, both in the probiotic and the placebo group,
confirming the absolute importance of the starting feeding type in
shaping the gut microbiota and, in particular, in reducing gram-
negative bacteria amount. However, in bottle-fed infants, the
mean counts of B. fragilis were higher at the end of the treatment
in the placebo group with respect to the probiotic one, thus
indicating a possible positive effect of the B. breve administration
at least before weaning. The increase of B. breve is also observed
in breast-fed newborns not treated with probiotics and this, as
already mentioned before, once more highlights the positive role
of breast milk in shaping the bifidobacteria community, also
considering that B. breve is one of the most abundant species
in the newborn gut (50). This increase is also supported by the
presence of peptides and oligosaccharides in the humanmilk that
provide the stimulation of the growth of bifidobacteria (47).
In addition to the microbial data, this study aims at
monitoring the typical gastrointestinal symptoms of colics, i.e.,
regurgitation, vomit and constipation, all of them difficult-
to-handle problems for caregivers. Results obtained from the
applied models showed a decreased number of evacuations and
an enhancement of stool consistency in breast-fed newborns
after 90 days of probiotics. In addition, bottle-fed newborns
showed an improvement of stool color. These data suggested
an amelioration in the gastrointestinal transit which can be
attributed to the probiotic intake. Moreover, the number of
regurgitations and episodes of vomit was reduced after probiotic
treatment. Similar results have already been demonstrated with
a supplementation of L. reuteri (6). The reduction of these
symptoms is particularly important because they also reduce
parental anxiety and related consequences.
The reduction in regurgitation and vomit was not shown in
the group of bottle-fed newborns. This result can be affected by
the small size of the bottle-fed group of newborns. The study
was not designed to evaluate differences between the two feeding
regimens and authors are aware that the bottle-fed group was
underpowered to reach the clinical outcomes. However, data
related to the different feeding should be analyzed separately
due to the unexpected significant differences in microbial
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composition at baseline. On the other hand, those breast-fed at
the recruitment who switched to bottle-or mixed-feeding had an
improvement with reduction of regurgitation episodes. This is
an important achievement also considering that the number of
newborns bottle-fed since the beginning of life is generally low
as, usually, a starting feeding with mother milk is applied (51).
In this study, daily infant crying time did not show any
difference between probiotic and placebo groups in spite of
the improvement of the gastric transit due to the probiotic
administration. This result is contrasting with other reports in
literature. Several causes could be considered, first of all the
inaccuracy of the count of minutes of crying through self-report
diaries, although validated, in particular for such a prolonged
time. Analysis of any existing tool to monitor daily crying have
been demonstrated to be inaccurate, difficult or not validated for
a prolonged time of observation (52). Moreover, we evaluated
the effects over 3 months, whereas the majority of the studies
are related to probiotic treatment no longer than 4 weeks (1,
53). Moreover, other confounding factors may have a role after
the second months of life, in particular, if we consider the
efficacy on the other gastro-intestinal parameters. Furthermore,
the prevalence of colic infants was similar but very low in
both placebo and probiotic groups. This is a consequence of
considering in the study healthy newborns. Studies including
only colic infants are needed in the future.
The main unexpected and interesting result of the study was
related to the auxological parameters. Clinical trials on the effect
of probiotics on neonatal growth parameters are scarce. In our
population, infants born by cesarean section had a lower catch-
up growth in weight if treated with the probiotic. This result is
of crucial interest in planning further intervention studies. Gut
colonization by environmental microorganisms occurs during
or immediately after the birth, whereas, in infants delivered by
cesarean section, gut colonization is delayed and often altered,
in particular modifying Bifidobacterium and Lactobacillus counts
(25). Increasing epidemiological data suggested that children
born by cesarean section have an increased risk to develop
obesity later in life (54, 55). How the genetic background
and the environment affect mechanisms that control appetite,
weight regulation and metabolic disorders linked to overweight,
and the immune education is poorly understood. Gestation,
delivery, postnatal nutrition (lactation and weaning) have been
identified as critical periods to program the nutritional and
hormonal control of the offspring. Some Authors suggest that
the sudden modification of the initial conditions may disrupt the
physiological process predisposing to certain diseases (46, 56, 57)
and alterations in the precocious colonization have a role (54, 55).
Our data suggest that a treatment with B. breve strains in the first
3 months of life is able to influence the microbiota composition
and this is associated with a concomitant lower weight gain in
the population at higher risk of metabolic disturbances in later
life. Other authors failed to show changes in weight in neonates
treated with other probiotics (53, 58). Differences should be
secondary to the strains or, more probably, to the timing of the
treatment being our protocol designed on 3 months, differently
from the majority of the studies which followed infants for
1 month. In our study, the effect on weight was associated
to an increase in head circumference. These data suggest that
the probiotic treatment protects against a growth failure, as
recently demonstrated for a multi-strain probiotic containing
bifidobacteria in very low birth weight children exposed to
antibiotics (59).
The main limitation of this study is related to the small
sample size of the bottle-fed population. However, this is a
consequence of the inclusion criteria (healthy neonates) in
a condition in which breastfeeding must be the first choice
(51). Furthermore, although we used a validated questionnaire
for daily infant crying, the other questionnaires used to
record other gastrointestinal symptoms are not validated. On
the contrary, the strengths of our study are a treatment
prolonged for more than 4 weeks, the inclusion of neonates
not exposed to antibiotics, the evaluation of many confounders,
in particular regarding birth and changes in feeding over
time.
In conclusion, our study demonstrates that the administered
B. breve strains can reach the intestine of healthy newborns,
preventing functional gastrointestinal disorders and reducing
the precocious weight gain, at least in the absence of antibiotic
interferences. No adverse events were reported, suggesting the
safety of the product in this regimen. Prospective longitudinal
evaluations should be useful to further investigate if a precocious
short treatment in this critical window has also advantages later
in life.
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